Insmed Projects $1B Revenue for BRINSUPRI in 2026 Amid Strong Growth
Event summary
- Insmed anticipates BRINSUPRI revenues of at least $1 billion for 2026, up from $172.7 million in 2025.
- ARIKAYCE revenues grew 19% in 2025, exceeding guidance with $433.8 million in total revenue.
- Company ends 2025 with $1.4 billion in cash, cash equivalents, and marketable securities.
- FDA granted orphan drug designation to treprostinil palmitil for pulmonary arterial hypertension treatment.
- Phase 3 ENCORE trial results for ARIKAYCE expected in Q1 2026, with potential label expansion submissions in H2 2026.
The big picture
Insmed's strong financial performance in 2025, driven by BRINSUPRI's successful U.S. launch and ARIKAYCE's continued growth, positions the company for significant expansion in 2026. The strategic focus on regulatory milestones and pipeline advancements reflects Insmed's push to become a leader in respiratory and rare disease treatments. With $1.4 billion in cash reserves, the company has the financial flexibility to invest in both commercial and R&D initiatives.
What we're watching
- Commercial Momentum
- Whether Insmed can sustain BRINSUPRI's rapid revenue growth and meet its $1 billion target for 2026.
- Regulatory Milestones
- The pace at which Insmed secures regulatory approvals for ARIKAYCE label expansion and TPIP advancements.
- Pipeline Execution
- How Insmed balances its commercial expansion with the development of its diverse pipeline, including gene therapies.
Our editorial coverage:
Related topics